好中球減少症用生物製剤治療の世界市場レポート 2024年

好中球減少症用生物製剤治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.5%の年間複合成長率（CAGR）で181億米ドルに成長すると予想されます。予測期間中に予想される拡大は、医療費管理、患者中心のケアモデルの導入、併用療法の開発の進歩、規制の変更と承認、個別化医療アプローチの採用に関連しています。予測期間中に予測される主要動向には、世界市場へのアクセスの向上、製造技術の進歩、治療プロトコルの合理化、バイオシミラーの普及、と長時間作用型製剤の開発が含まれます。

世界のがん症例の増加は、好中球減少症の生物学的製剤市場の拡大に寄与すると予想されます。がんの発生率の増加と、化学療法を受ける人の増加により、好中球減少症の有病率が増加しています。たとえば、2022年 1月の時点で、米国がん協会は、米国で約190万人が新たにがんと診断され、60万9,360人ががん関連で死亡し、1日あたり平均約1,670人が死亡すると予測しています。肺がん、前立腺がん、腸がん、と女性の乳がんは、合わせて世界中の新規がん症例全体の43%を占めています。その結果、世界のがん罹患率の急増により、今後数年間で好中球減少症用生物製剤治療の需要が高まると予想されます。

医療の研究開発を目的とした政府の取り組みにより、好中球減少症用生物製剤治療市場の成長を推進する態勢が整っています。これらの取り組みには、特定の問題に対処したり、定義された目標を達成したり、社会に前向きな変化をもたらしたりするために、さまざまなレベル（地方、地域、国家、または国際）で政府当局が実施する特定の行動、プログラム、政策、またはプロジェクトが含まれます。さまざまな政府機関が、好中球減少症用生物製剤治療などのさまざまな側面をサポートする医療イニシアチブを立ち上げています。その一例として、2022年に英国政府は保健社会福祉省を通じて、医療の調査と製造を促進するために2億6,000万ポンド（2億7,065万米ドル）の資金提供を約束すると発表しました。 BEISとDHSCによるこの割り当ては、新しいプライバシー保護プラットフォームと臨床調査サービスを通じて、診断と治療におけるNHS主導の健康調査を支援することを目的としています。さらに、英国におけるライフサイエンス製造の拡大を促進するために、6,000万ポンド（6,360万米ドル）が割り当てられました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の好中球減少症生物製剤治療市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の好中球減少症用生物製剤治療市場規模実績と成長、2018～2023年
• 世界の好中球減少症用生物製剤治療市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の好中球減少症用生物製剤治療市場、薬剤タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• フィルグラスチム
• ペグフィルグラスチム
• レノグラスチム
• リペグフィルグラスチム
• サルグラモスチム
• 世界の好中球減少症用生物製剤治療市場、治療タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 抗生物質
• 顆粒球コロニー刺激因子（G-CSF）
• 抗真菌薬
• その他
• 世界の好中球減少症用生物製剤治療市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 小売薬局
• 病院薬局
• オンライン薬局

第7章 地域と国の分析

• 世界の好中球減少症用生物製剤治療市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の好中球減少症用生物製剤治療市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 好中球減少症用生物製剤治療市場の競合情勢
• 好中球減少症用生物製剤治療市場の企業プロファイル
  • CVS Health Corporation
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi SA
  • Amgen Inc.

第31章 その他の大手と革新的な企業

• Mylan NV
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Kyowa Kirin Co. Ltd.
• Tianjin CanSino Biotechnology Inc.
• Dr Reddy's Laboratories Ltd.
• The Unmanned Surface Vehicles Private Limited
• Biocon Limited
• Dong-A ST Co. Ltd.
• Akthelia Pharmaceuticals Ltd.
• Generon（Shanghai）Corporation Ltd.
• Sandoz International GmbH
• Enzychem Lifesciences Corporation
• Aprilbio Co. Ltd.
• Spectrum Pharmaceuticals Inc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Neutropenia biologic drug treatment involves the use of medications aimed at reducing fevers, preventing potential infections, and stimulating bone marrow activity to enhance neutrophil production. Neutropenia, characterized by a deficiency of neutrophils, a specific type of white blood cell, necessitates such interventions.

The primary drugs utilized in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim, a synthetic version of granulocyte colony-stimulating protein, is administered through injections to elevate neutrophil production following chemotherapy. Various types of treatments encompass antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, among others. These medications are accessible through diverse channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The neutropenia biologic drug treatment market research report is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neutropenia biologic drug treatment market size has grown strongly in recent years. It will grow from $13.22 billion in 2023 to $14.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The expansion observed in the historical period can be ascribed to factors such as improved market access and reimbursement, increased patient advocacy and awareness, enhanced physician education and training, advancements in biologic drug development, and the successful outcomes of clinical trials.

The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $18.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The expansion anticipated in the forecast period is linked to healthcare cost management, the implementation of patient-centric care models, progress in the development of combination therapies, regulatory changes and approvals, and the adoption of personalized medicine approaches. Key trends projected for the forecast period encompass increased global market accessibility, advancements in manufacturing techniques, streamlining of treatment protocols, the uptake of biosimilars, and the development of long-acting formulations.

The increase in global cancer cases is expected to contribute to the expansion of the neutropenia biologic drugs market. The growing incidence of cancer, coupled with a rise in individuals undergoing chemotherapy, has led to an increased prevalence of neutropenia. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities per day. Lung, prostate, bowel, and female breast cancer collectively represent 43 percent of all new cancer cases worldwide. Consequently, the surge in global cancer incidence rates is anticipated to drive demand for neutropenia biologic drug treatment in the coming years.

Government initiatives aimed at research and development in healthcare are poised to propel the Neutropenia biologic drug treatment market's growth. These initiatives encompass specific actions, programs, policies, or projects undertaken by government authorities at different levels (local, regional, national, or international) to address specific issues, achieve defined goals, or bring about positive changes in society. Various government bodies are launching healthcare initiatives to support different facets, including neutropenia biologic drug treatment. As an illustration, in 2022, the UK government, through the Department of Health and Social Care, announced a funding commitment of £260 million (US $270.65 million) to boost healthcare research and manufacturing. This allocation by BEIS and DHSC is intended to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was earmarked to facilitate the expansion of life sciences manufacturing in the UK.

The neutropenia biologic drug treatment market is expected to face challenges with the introduction of biosimilars following the expiration of patents. Biosimilars are therapeutic agents that closely resemble the original biological products in action but are available at a lower cost. Priced at around 70% of branded drugs, biosimilars have the potential to replace expensive branded alternatives. For example, in May 2022, Biocon Biologics Limited, an Indian biopharmaceutical company, collaborated with Viatris Inc., a US-based healthcare and biopharmaceutical company, to launch Abevmy (bBevacizumab) for the treatment of various cancers, offering a more cost-effective alternative.

Companies in the neutropenia biologic drug treatment market are increasingly investing in the development of innovative drug delivery systems to enhance therapeutic responses and increase efficacy while minimizing side effects. In February 2021, Asalyxa Bio completed its formation and seed funding, advancing ASX-100 into first-in-human trials. ASX-100, a novel spherical particle, releases anti-inflammatory agent salicylic acid directly to over-reactive immune cells, providing a targeted treatment for severe neutrophil-mediated diseases.

Major players in the neutropenia biologic drug treatment market are focusing on the development of innovative biosimilars, such as pegfilgrastim-pbbk (Fylnetra), to drive market revenues. For instance, in May 2023, Amneal Pharmaceuticals Inc. launched Fylnetra, a biosimilar referencing Neulasta and approved by the Food and Drug Administration (FDA) for the treatment of neutropenia. Fylnetra is available in a convenient pre-filled single-dose syringe.

In November 2022, Biocon Biologics, specializing in the development of biological drugs, acquired Viatris, a US-based company known for developing neutropenia biologic drugs such as pegfilgrastim. This acquisition further strengthens Biocon Biologics' capabilities in research and development, global-scale manufacturing, and commercialization in emerging markets within the biosimilars sector.

Major companies operating in the neutropenia biologic drug treatment market report are CVS Health Corporation, Pfizer Inc., Novartis International AG, Sanofi SA, Amgen Inc., Mylan NV, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co. Ltd., Tianjin CanSino Biotechnology Inc., Dr Reddy's Laboratories Ltd., The Unmanned Surface Vehicles Private Limited, Biocon Limited, Dong-A ST Co. Ltd., Akthelia Pharmaceuticals Ltd., Generon (Shanghai) Corporation Ltd., Sandoz International GmbH, Enzychem Lifesciences Corporation, Aprilbio Co. Ltd., Spectrum Pharmaceuticals Inc., S&D Pharma SK sro, Partner Therapeutics Inc., PhytoHealth Corporation, X4 Pharmaceuticals Inc., BeyondSpring Inc., Tanvex BioPharma Inc., Myelo Therapeutics GmbH, Cellerant Therapeutics Inc., Toko Pharmaceutical Industries Co. Ltd., Statera Biopharma Inc.

North America was the largest region in the neutropenia biologic drug treatment market in 2023. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neutropenia Biologic Drug Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neutropenia biologic drug treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neutropenia biologic drug treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neutropenia biologic drug treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Type: Filgrastim; Pegfilgrastim; Lenograstim; Lipegfilgrastim; Sargramostim
• 2) By Treatment Type: Antibiotic Drugs; Granulocyte-Colony-Stimulating Factor (G-CSF); Antifungal Drugs; Other Treatment Types
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
• Companies Mentioned: CVS Health Corporation; Pfizer Inc.; Novartis International AG; Sanofi SA; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neutropenia Biologic Drug Treatment Market Characteristics

3. Neutropenia Biologic Drug Treatment Market Trends And Strategies

4. Neutropenia Biologic Drug Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Neutropenia Biologic Drug Treatment Market Size and Growth

• 5.1. Global Neutropenia Biologic Drug Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Neutropenia Biologic Drug Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Neutropenia Biologic Drug Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neutropenia Biologic Drug Treatment Market Segmentation

• 6.1. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Filgrastim
• Pegfilgrastim
• Lenograstim
• Lipegfilgrastim
• Sargramostim
• 6.2. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antibiotic Drugs
• Granulocyte-Colony-Stimulating Factor (G-CSF)
• Antifungal Drugs
• Other Treatment Types
• 6.3. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

7. Neutropenia Biologic Drug Treatment Market Regional And Country Analysis

• 7.1. Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neutropenia Biologic Drug Treatment Market

• 8.1. Asia-Pacific Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neutropenia Biologic Drug Treatment Market

• 9.1. China Neutropenia Biologic Drug Treatment Market Overview
• 9.2. China Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neutropenia Biologic Drug Treatment Market

• 10.1. India Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neutropenia Biologic Drug Treatment Market

• 11.1. Japan Neutropenia Biologic Drug Treatment Market Overview
• 11.2. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neutropenia Biologic Drug Treatment Market

• 12.1. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neutropenia Biologic Drug Treatment Market

• 13.1. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neutropenia Biologic Drug Treatment Market

• 14.1. South Korea Neutropenia Biologic Drug Treatment Market Overview
• 14.2. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neutropenia Biologic Drug Treatment Market

• 15.1. Western Europe Neutropenia Biologic Drug Treatment Market Overview
• 15.2. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neutropenia Biologic Drug Treatment Market

• 16.1. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neutropenia Biologic Drug Treatment Market

• 17.1. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neutropenia Biologic Drug Treatment Market

• 18.1. France Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neutropenia Biologic Drug Treatment Market

• 19.1. Italy Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neutropenia Biologic Drug Treatment Market

• 20.1. Spain Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neutropenia Biologic Drug Treatment Market

• 21.1. Eastern Europe Neutropenia Biologic Drug Treatment Market Overview
• 21.2. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neutropenia Biologic Drug Treatment Market

• 22.1. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neutropenia Biologic Drug Treatment Market

• 23.1. North America Neutropenia Biologic Drug Treatment Market Overview
• 23.2. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neutropenia Biologic Drug Treatment Market

• 24.1. USA Neutropenia Biologic Drug Treatment Market Overview
• 24.2. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neutropenia Biologic Drug Treatment Market

• 25.1. Canada Neutropenia Biologic Drug Treatment Market Overview
• 25.2. Canada Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neutropenia Biologic Drug Treatment Market

• 26.1. South America Neutropenia Biologic Drug Treatment Market Overview
• 26.2. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neutropenia Biologic Drug Treatment Market

• 27.1. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neutropenia Biologic Drug Treatment Market

• 28.1. Middle East Neutropenia Biologic Drug Treatment Market Overview
• 28.2. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neutropenia Biologic Drug Treatment Market

• 29.1. Africa Neutropenia Biologic Drug Treatment Market Overview
• 29.2. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neutropenia Biologic Drug Treatment Market Competitive Landscape And Company Profiles

• 30.1. Neutropenia Biologic Drug Treatment Market Competitive Landscape
• 30.2. Neutropenia Biologic Drug Treatment Market Company Profiles
  • 30.2.1. CVS Health Corporation
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis International AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi SA
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Amgen Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Neutropenia Biologic Drug Treatment Market Other Major And Innovative Companies

• 31.1. Mylan NV
• 31.2. Baxter International Inc.
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Kyowa Kirin Co. Ltd.
• 31.5. Tianjin CanSino Biotechnology Inc.
• 31.6. Dr Reddy's Laboratories Ltd.
• 31.7. The Unmanned Surface Vehicles Private Limited
• 31.8. Biocon Limited
• 31.9. Dong-A ST Co. Ltd.
• 31.10. Akthelia Pharmaceuticals Ltd.
• 31.11. Generon (Shanghai) Corporation Ltd.
• 31.12. Sandoz International GmbH
• 31.13. Enzychem Lifesciences Corporation
• 31.14. Aprilbio Co. Ltd.
• 31.15. Spectrum Pharmaceuticals Inc

32. Global Neutropenia Biologic Drug Treatment Market Competitive Benchmarking

33. Global Neutropenia Biologic Drug Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neutropenia Biologic Drug Treatment Market

35. Neutropenia Biologic Drug Treatment Market Future Outlook and Potential Analysis

• 35.1 Neutropenia Biologic Drug Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Neutropenia Biologic Drug Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Neutropenia Biologic Drug Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer